Development of Nanocrystal Formulations With Improved Dissolution And Bioavailability for BCS Classs-II Drug- Quitapine. Journal of Pharmaceutical Negative Results 2022, 5113-5120. https://doi.org/10.47750/pnr.2022.13.S08.670.